|
1
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani
PC, et al: Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the
urothelium. J Urol. 133:403–407. 1985.PubMed/NCBI View Article : Google Scholar
|
|
2
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Robinson P, Maase H, Bhalla S, Kielhorn A,
Aristides M, Brown A and Tilden D: Cost-utility analysis of the GC
versus MVAC regimens for the treatment of locally advanced or
metastatic bladder cancer. Expert Rev Pharmacoecon Outcomes Res.
4:27–38. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Azuma T, Matayoshi Y, Sato Y, Sato Y,
Nagase Y and Oshi M: The safety and effect of chemotherapy with
short hydration for urothelial cancer on patients' quality of life.
Jpn J Clin Oncol. 46:958–963. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tiseo M, Martelli O, Mancuso A, Sormani
MP, Bruzzi P, Di Salvia R, De Marinis F and Ardizzoni A: Short
hydration regimen and nephrotoxicity of intermediate to high-dose
cisplatin-based chemotherapy for outpatient treatment in lung
cancer and mesothelioma. Tumori. 93:138–144. 2007.PubMed/NCBI
|
|
6
|
Abdel-Rahman O, Elsayed Z and Elhalawani
H: Gemcitabine-based chemotherapy for advanced biliary tract
carcinomas. Cochrane Database Syst Rev. 4(CD011746)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Accessed Sep 12, 2020.
|
|
8
|
Dash A, Galsky MD, Vickers AJ, Serio AM,
Koppie TM, Dalbagni G and Bochner BH: Impact of renal impairment on
eligibility for adjuvant cisplatin-based chemotherapy in patients
with urothelial carcinoma of the bladder. Cancer. 107:506–513.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kaag MG, O'Malley RL, O'Malley P, Godoy G,
Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G,
et al: Changes in renal function following nephroureterectomy may
affect the use of perioperative chemotherapy. Eur Urol. 58:581–587.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Basch E, Prestrud AA, Hesketh PJ, Kris MG,
Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM,
Freundlich B, et al: American Society of Clinical Oncology.
Antiemetics: American Society of Clinical Oncology clinical
practice guideline update. J Clin Oncol. 29:4189–4198.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Naiki T, Sugiyama Y, Tasaki Y, Iida K,
Etani T, Hamamoto S, Nagai T, Nozaki S, Ando R, Kawai N, et al:
Efficacy of a newly modified short hydration method for gemcitabine
and cisplatin combination chemotherapy in patients with urothelial
carcinoma. Oncology. 98:612–620. 2020.PubMed/NCBI View Article : Google Scholar
|
